Several studies have demonstrated that epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) could noticeably improve survival of EGFR positive mutation advanced NSCLC patients [19–22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.